Immuneering

IMRX NASDAQ IPO2021

about IMRX

Immuneering is a biopharmaceutical company focused on developing innovative treatments, with a pipeline that includes products targeting cancer immunotherapy and rare diseases, utilizing cutting-edge technology to advance drug discovery and development.

type open high low market
cap
volume
stock $4.68 $4.92 $4.20 $305.42M 3.66M
eps price to
earnings
price to
sales
operating
margin
profit
margin
yield
-$0.38 n/a n/a 0% 0% 0%